Unlocking health insights with compreshensive EHR data

Truveta Data is the most complete, timely, and clean EHR data

Regulatory-grade EHR data for more than 100 million patients, linked with claims and SDOH, enabling research on any drug, disease, or device

100M+

patients and growing

5B+

clinical notes

150K+

unique medical devices

5+

years patient history

440+

SDOH attributes

Trusted by leading life science, government, and healthcare organizations

Truveta solutions

Clinical trials

Accelerate clinical trial timelines by enrolling the right patients faster, with direct access to community health systems.

Testing I/E criteria to de-risk clinical programs

Diagram detailing inclusion and exclusion criteria applied to a heart failure population. The criteria encompass medication use, length of stay, outpatient encounters, laboratory results, comorbidities, and device use. The visual representation offers a comprehensive overview of the selection criteria, aiding in understanding the parameters used to define the study population.

Sample heart failure population with inclusion/exclusion criteria applied

 

Safety monitoring

Fulfill post-market safety requirements at half the cost and twice as fast with regulatory-grade data.

Tracking adverse events post-vaccination

Dashboard showing adverse events by demographic, manufacturer, comorbidity, dose, and more within Truveta Studio

 

Comparative effectiveness

Establish product differentiation and increase market adoption with timely patient-level outcomes and SDOH data.

Comparing outcomes of novel interventions

Comparison table from a scientific publication illustrating bleeding events associated with two medical devices for treating pulmonary embolism: the USCDT (Unspecified Superiority Clot Dissolver) and MT (Standard Mechanical Thrombectomy). The data is presented for two distinct time periods—2009 to 2023 (primary analysis) and 2018 to 2023 (contemporary analysis). Bleeding events are categorized into six types, with results presented as counts and percentages. Statistical significance is indicated by p-values, providing insights into the safety profiles of the two devices over time.

Comparative bleeding incidence 7 days post-procedure for pulmonary embolism interventions

 

Label expansion

Identify emerging opportunities to expand product usage and improve care with timely patient-level outcomes data.

Monitoring on- and off-label prescribing patterns

Stacked line chart depicting trends in on-and off-label GLP-1 prescribing for first-time prescriptions, categorized by indication: type 2 Diabetes and obesity. The type 2 diabetes graph illustrates prescribing patterns for four specific drugs between January 2018 and April 2023, while the obesity graph displays data for two drugs. The y-axis represents the number of prescriptions, showcasing variations in prescribing practices for GLP-1 drugs for both medical conditions.

First-time GLP-1 prescriptions by medication by labeled indication and on- and off-label use

 

Closing care gaps

 Collaborate with health systems to advance adoption of insights into patient care.

Assessing the clinical consequences of diagnostic delays

Table displaying diagnoses of depression, anxiety, substance use disorder, or surgery for abscess, cyst, or boils before the primary diagnosis, Hidradenitis Suppurativa (HS), categorized by the length of HS diagnostic delay - short, medium, and long. The results present counts within each diagnostic delay category, alongside the number and percentage of individuals with each additional diagnosis or event. This analysis provides insights into the associations between diagnostic delays and the occurrence of specific health conditions or events prior to the primary diagnosis.

Rates of mental health diagnoses and surgery by length of HS diagnostic delay

 

Truveta solutions

Clinical trials

Safety monitoring

Comparative effectiveness

Label expansion

Closing care gaps

Clinical trials

Accelerate clinical trial timelines and speed time to market by identifying the right patients faster.

Testing I/E criteria to de-risk clinical programs

October 2023 Respiratory Viruses hospitalizations trend report

Sample heart failure population with inclusion/exclusion criteria applied

Safety monitoring

Fulfill post-market safety requirements at half the cost and twice as fast with regulatory-grade data.

Post-approval safety studies are costly, as are the consequences of delayed signal detection. Truveta enables life sciences companies to:

Tracking adverse events post-vaccination

October 2023 Respiratory Viruses hospitalizations trend report

Dashboard showing adverse events by demographic, manufacturer, comorbidity, dose, and more within Truveta Studio

Comparative effectiveness

Establish product differentiation and increase market adoption with timely patient-level outcomes and SDOH data.

Comparing outcomes of novel interventions

October 2023 Respiratory Viruses hospitalizations trend report

Comparative bleeding incidence 7 days post-procedure for pulmonary embolism interventions

Label expansion

Identify emerging opportunities to expand product usage and improve care with timely patient-level outcomes data.

Monitoring on- and off-label prescribing patterns

October 2023 Respiratory Viruses hospitalizations trend report

First-time GLP-1 prescriptions by medication by labeled indication and on- and off-label use

Closing care gaps

Collaborate with health systems to advance adoption of insights into patient care.

Assessing the clinical consequences of diagnostic delays

October 2023 Respiratory Viruses hospitalizations trend report

Rates of mental health diagnoses and surgery by length of HS diagnostic delay

Case study

Comparing the safety of novel pulmonary embolism devices

Real-world data is essential for filling knowledge gaps on drugs and devices. To assess the real-world safety of its EKOS device versus a competitor device, Boston Scientific enlisted independent researchers to compare major bleeding event risks using Truveta Data.

See the power of the Truveta EHR Data in action

Ready to accelerate your research with complete, representative, and timely real-world data?

Let’s chat